Influenza virus

Clinical Virology: Third Edition

Volumn , Issue , 2022, Pages 943-976

  Hayden, Frederick G ^a   Palese, Peter ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral chemoprophylaxis; Immunogenicity; Influenza virus; Live attenuated influenza virus vaccines (LAIV); Pathogenicity

Indexed keywords

EID: 85152833080     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555815981.ch42     Document Type: Chapter

References (172)

1. Akarsu, H., W. P. Burmeister, C. Petosa, I. Petit, C. W. Muller, R. W. Ruigrok, F. Baudin. 2003. Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2). EMBO J. 22:4646-4655.
2. Aoki, F. Y., G. Boivin, N. Roberts. 2007. Influenza virus susceptibility resistance to oseltamivir. Antivir. Ther. 12(4 Pt. B):603-616.
3. Baskin, C. R., H. Bielefeldt-Ohmann, A. Garcia-Sastre, T. M. Tumpey, N. Van Hoeven, V. S. Carter, M. J. Thomas, S. Proll, A. Solorzano, R. Billharz, J. L. Fornek, S. Thomas, C. H. Chen, E. A. Clark, K. Murali-Krishna, M.G. Katze. 2007. Functional genomic serological analysis of the protective immune response resulting from vaccination of macaques with an NS1truncated influenza virus. J. Virol. 81:11817-11827.
4. Bean, B., B. M. Moore, B. Sterner, L. R. Peterson, D. N. Gerding, H.H. Balfour, Jr. 1982. Survival of influenza viruses on environmental surfaces. J. Infect. Dis. 146:47-51.
5. Beare, A. S., R.G. Webster. 1991. Replication of avian influenza viruses in humans. Arch. Virol. 119 :37-42.
6. Belser, J. A., X. Lu, K. Szretter, X. Jin, L. M. Aschenbrenner, S. Lee, S. Hawley, D. H. Kim, M. P. Malakhov, M. Yu, F. Fang, J.M. Katz. 2007. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 196: 1493-1499.
7. Belshe, R., P. Mendelman, J. J. Treanor, J. King, W. C. Gruber, P. A. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, D. Iacuzio, M. Wolff. 1998. Efficacy of a trivalent live attenuated intranasal influenza vaccine in children. N. Engl. J. Med. 338: 1405-1412.
8. Belshe, R. B., K. M. Edwards, T. Vesikari, S. V. Black, R. E. Walker, M. Hultquist, G. Kemble, E.M. Connor for the CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza vaccine in infants young children. N. Engl. J. Med. 356:685-696.
9. Bernstein, D. I., K. M. Edwards, C. L. Dekker, R. Belshe, H. K. B. Talbot, I. L. Graham, D. L. Noah, F. He, H. Hill. 2008. Effects of adjuvants on the safety immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197:1-9.
10. Boone, S. A., C.P. Gerba. 2005. The occurrence of influenza A virus on household day care center fomites. J. Infect. 51:103-109.
11. Brankston, G., L. Gitterman, Z. Hirji, C. Lemieux, M. Gardam. 2007. Transmission of influenza A in human beings. Lancet Infect. Dis. 7:257-265.
12. Brundage, J. F. 2006. Interactions between influenza bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. 6:303-312.
13. Buonagurio, D. A., T. M. Bechert, C. F. Yang, L. Shutyak, G. A. D'Arco, Y. Kazachkov, H. P. Wang, E. A. Rojas, R. E. O'Neill, R. R. Spaete, K. L. Coelingh, T. J. Zamb, M. S. Sidhu, S.A. Udem. 2006. Genetic stability of live, cold-adapted influenza virus components of the FluMist(R)/CAIV-T vaccine throughout the manufacturing process. Vaccine 24:2151-2160.
14. Bush, R. M., C. A. Bender, K. Subbarao, N. J. Cox, W.M. Fitch. 1999. Predicting the evolution of human influenza A. Science 286:1921-1925.
15. Call, S. A., M. A. Vollenweider, C. A. Hornung, D. L. Simel, W.P. McKinney. 2005. Does this patient have influenza? JAMA 293:987-997.
16. Cauchemez, S., A. J. Valleron, P. Y. Boelle, A. Flahault, N.M. Ferguson. 2008. Estimating the impact of school closure on influenza transmission from sentinel data. Nature 452:750-754.
17. Centers for Disease Control Prevention. 2007. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States-easy, targeted, layered use of nonpharmaceutical interventions. http://www.pandemicflu.gov/plan/ community/community mitigation.pdf.
18. Chemaly, R. F., H. A. Torres, E. A. Aguilera, G. Mattiuzzi, M. Cabanillas, H. Kantarjian, V. Gonzalez, A. Safdar, I.I. Raad. 2007. Neuraminidase inhibitors improve outcome of patients with leukemia influenza: an observational study. Clin. Infect. Dis. 44:964-967.
19. Chen, W., P. A. Calvo, D. Malide, J. Gibbs, U. Schubert, I. Bacik, S. Basta, R. O'Neill, J. Schickli, P. Palese, P. Henklein, J. R. Bennink, J.W. Yewdell. 2001. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7:1306-1312.
20. Colman, P. M. 1989. Influenza virus neuraminidase: enzyme antigen, p. 175-218. In R.M. Krug (ed.), The Influenza Viruses. Plenum Press, New York, NY.
21. Colman, P. M., J. N. Varghese, W.G. Laver. 1983. Structure of the catalytic antigenic sites in influenza virus neuraminidase. Nature 303:41-44.
22. Couch, R. B., P. Winokur, R. Brady, R. Belshe, W. H. Chen, T. R. Cate, B. Sigurdardottir, A. Hoeper, I. L. Graham, R. Edelman, F. He, D. Nino, J. Capellan, F.L. Ruben. 2007. Safety immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25:7656-7663.
23. Crescenzo-Chaigne, B., S. van der Werf. 2007. Rescue of influenza C virus from recombinant DNA. J. Virol. 81:11282-11289.
24. Davies, J. R., E.A. Grilli. 1989. Natural or vaccineinduced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. Infect. 102:325-333.
25. De Benedictis, P., M. S. Beato, I. Capua. 2007. Inactivation of avian influenza viruses by chemical agents physical conditions: a review. Zoonoses Public Health 54:51-68.
26. de Jong, M. D., C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith, T. N. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, P. T. Qui, B. V. Cam, D. Q. Ha, Y. Guan, J. S. Peiris, N. T. Chinh, T. T. Hien, J. Farrar. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load hypercytokinemia. Nat. Med. 12:1203-1207.
27. de Jong, M. D., T. T. Thanh, T. H. Khanh, V. M. Hien, G. J. D. Smith, N. V. Chau, B. V. Cam, P. T. Qui, D. Q. Ha, Y. Guan, J. S. M. Peiris, T. T. Hien, J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
28. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. Smith, Y. Zhang, Y. Shu, L. Gubareva, N. Cox, A.I. Klimov. 2008. Surveillance of resistance to adamantanes among influenza A(H3N2) A(H1N1) viruses isolated worldwide. J.Infect. Dis. 196:249-257.
29. Dodds, L., S. A. McNeil, D. B. Fell, V. M. Allen, A. Coombs, J. Scott, N. MacDonald. 2007. Impact of influenza exposure on rates of hospital admissions physician visits because of respiratory illness among pregnant women. Can. Med. Assoc. J. 176:463-468.
30. Dowdle, W. R. 1999. Influenza A virus recycling revisited. Bull. W. H. O. 77:820-828.
31. Englund, J. A., R. E. Champlin, P. R. Wyde, H. Kantarjian, R. L. Atmar, J. J. Tarrand, H. Yousuf, H. Regnery, A. I. Klimov, N. Cox, E. Whimbey. 1998. Common emergence of amantadine rimantadine resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26:1418-1424.
32. Epstein, J. M., D. M. Goedecke, F. Yu, R. J. Morris, D. K. Wagener, G.V. Bobashev. 2007. Controlling pandemic flu: the value of international air travel restrictions. PLoS ONE 2(5):e401.
33. Ferguson, N. M., D. A. T. Cummings, S. Cauchemez, C. Fraser, S. Riley, A. Meeyai, S. Iamsirithaworn, D.S. Burke. 2005. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437:209214.
34. Fiers, W., M. De Filette, A. Birkett, S. Neirynck, W. Min Jou. 2004. A ''universal'' human influenza A vaccine. Virus Res. 103(1-2): 173-176.
35. Fiore, A. E., D. K. Shay, P. Haber, J. Iskander, T. M. Uyeki, G. Mootrey, J. S. Bresee, N. Cox for the Centers for Disease Control Prevention. 2007. Prevention control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. Morb. Mortal. Wkly. Rep. 56(RR-6):1-54.
36. Flick, R., G. Hobom. 1999. Interaction of influenza virus polymerase with viral RNA in the 'corkscrew' conformation. J. Gen. Virol. 80(Pt. 10):2565-2572.
37. Fodor, E., L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, A. Garcia-Sastre. 1999. Rescue of influenza A virus from recombinant DNA. J. Virol. 73: 9679-9682.
38. Fodor, E., D. C. Pritlove, G.G. Brownlee. 1995. Characterization of the RNA-fork model of virion RNA in the initiation of transcription in influenza A virus. J. Virol. 69:4012-4019.
39. Fujii, K., Y. Fujii, T. Noda, Y. Muramoto, T. Watanabe, A. Takada, H. Goto, T. Horimoto, Y. Kawaoka. 2005. Importance of both the coding the segmentspecific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J. Virol. 79:3766-3774.
40. Fukuda, K., R. A. Levandowski, C. B. Bridges, N.J. Cox. 2004. Inactivated influenza vaccine, p. 339-370. In S.A. Plotkin, W.A. Orenstein (ed.), Vaccines. Elsevier, Philadelphia, PA.
41. Garcia-Sastre, A. 2006. Antiviral response in pandemic influenza viruses. Emerg. Infect. Dis. 12:44-47.
42. Garcia-Sastre, A., P. Palese. 1993. Genetic manipulation of negative-str RNA virus genomes. Annu. Rev. Microbiol. 47:765-790.
43. Gianfrani, C., C. Oseroff, J. Sidney, R. W. Chesnut, A. Sette. 2000. Human memory CTL response specific for influenza A virus is broad multispecific. Hum. Immunol. 61:438-452.
44. Glezen, W. P., R.B. Couch. 1997. Influenza viruses, p. 473-505. In A.S. Evans R.A. Kaslow (ed.), Viral Infections of Humans. Plenum Medical Book Company, New York, NY.
45. Glezen, W. P., L. H. Taber, A. L. Frank, W. C. Gruber, P.A. Piedra. 1997. Influenza virus infections in infants. Pediatr. Infect. Dis. J. 16:1065-1068.
46. Gomolin, I. H., H. B. Leib, N. H. Arden, F.T. Sherman. 1995. Control of influenza outbreaks in the nursing home: guidelines for diagnosis management. J. Am. Geriatr. Soc. 43:71-74.
47. Gravenstein, S. M. M. C., P. M. Drinka, D. M. Osterweil, M. M. Schilling, P. R. Krause, M. M. Elliott, P. P. Shult, A. M. Ambrozaitis, R. M. Kandel, E. M. Binder, J. M. Hammond, J. M. McElhaney, N. P. Flack, J. P. Daly, O.M. Keene. 2005. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J. Am. Med. Directors Assoc. 6:359-366.
48. Gu, J., Z. Xie, Z. Gao, J. Liu, C. Korteweg, J. Ye, L. T. Lau, J. Lu, Z. Gao, B. Zhang, M. A. McNutt, M. Lu, V. M. Anderson, E. Gong, A. C. H. Yu, W.I. Lipkin. 2007. H5N1 infection of the respiratory tract beyond: a molecular pathology study. Lancet 370:11371145.
49. Hageman, J. C., T. M. Uyeki, J. S. Francis, D. B. Jernigan, J. G. Wheeler, C. B. Bridges, S. J. Barenkamp, D. M. Sievert, A. Srinivasan, M. C. Doherty, L. K. McDougal, G. E. Killgore, U. A. Lopatin, R. Coffman, J. K. MacDonald, S. K. McAllister, G. E. Fosheim, J. B. Patel, L.C. McDonald. 2006. Severe communityacquired pneumonia due to Staphylococcus aureus, 200304 influenza season. Emerg. Infect. Dis. 12:894-899.
50. Hagen, M., T. D. Chung, J. A. Butcher, M. Krystal. 1994. Recombinant influenza virus polymerase: requirement of both 5' 3' viral ends for endonuclease activity. J. Virol. 68:1509-1515.
51. Hatakeyama, S., Y. Sakai-Tagawa, M. Kiso, H. Goto, C. Kawakami, K. Mitamura, N. Sugaya, Y. Suzuki, Y. Kawaoka. 2005. Enhanced expression of an a2, 6-linked sialic acid on MDCK cells improves isolation of human influenza viruses evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:41394146.
52. Hayden, F. G. 1997. Prevention treatment of influenza in immunocompromised patients. Am. J. Med. 102(3A):55-60.
53. Hayden, F. G., F.Y. Aoki. 2005. Amantadine, rimantadine, related agents, p. 705-729. In V.L. Yu, G. Edwards, P. S. McKinnon, C. Peloquin, G.D. Morse (ed.), Antimicrobial Therapy Vaccines. ESun Technologies, LLC, Pittsburgh, PA.
54. Hayden, F. G., F.Y. Aoki. 2005. Influenza neuraminidase inhibitors, p. 773-789. In V.L. Yu, G. Edwards, P. S. McKinnon, C. Peloquin, G.D. Morse (ed.), Antimicrobial Therapy Vaccines. ESun Technologies, LLC, Pittsburgh, PA.
55. Hayden, F. G., R. S. Fritz, M. Lobo, G. Alvord, W. Strober, S.E. Straus. 1998. Local systemic cytokine responses during experimental human influenza A virus infection. J. Clin. Investig. 101:643-649.
56. Hayden, F. G., A.T. Pavia. 2006. Antiviral management of seasonal pandemic influenza. J. Infect. Dis. 194(S2):S119-S126.
57. Hayward, A. C., R. Harling, S. Wetten, A. M. Johnson, S. Munro, J. Smedley, S. Murad, J.M. Watson. 2006. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, health service use among residents: cluster randomised controlled trial. Br. Med. J. 333:1241-1247.
58. Hoffmann, E., K. Mahmood, Z. Chen, C.-F. Yang, J. Spaete, H. B. Greenberg, M. L. Herlocher, H. Jin, G. Kemble. 2005. Multiple gene segments control the temperature sensitivity attenuation phenotypes of ca B/Ann Arbor/1/66. J. Virol. 79:11014-11021.
59. Hoffmann, E., K. Mahmood, C. F. Yang, R. G. Webster, H. B. Greenberg, G. Kemble. 2002. Rescue of influenza B virus from eight plasmids. Proc. Natl. Acad. Sci. USA 99:11411-11416.
60. Horimoto, T., Y. Kawaoka. 2005. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3:591-600.
61. Ilyushina, N. A., E. Hoffmann, R. Solomon, R. G. Webster, E.A. Govorkova. 2007. Amantadineoseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12:363-370.
62. Ison, M. G., L. V. Gubareva, R. L. Atmar, J. Treanor, F.G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
63. Jackson, D., A. Cadman, T. Zurcher, W.S. Barclay. 2002. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J. Virol. 76:11744-11747.
64. Jackson, D., H. J. Hossain, D. Hickman, D. R. Perez, R.A. Lamb. 2008. A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. Proc. Natl. Acad. Sci. USA 105: 4381-4386.
65. Jameson, J., J. Cruz, M. Terajima, F.A. Ennis. 1999. Human CD8+ CD4+ T lymphocyte memory to influenza A viruses of swine avian species. J. Immunol. 162:7578-7583.
66. Jin, H., B. Lu, H. Zhou, C. Ma, J. Zhao, C. F. Yang, G. Kemble, H. Greenberg. 2003. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (Flumist) derived from coldadapted A/Ann Arbor/6/60. Virology 306:18-24.
67. Johnson, N. P., J. Mueller. 2002. Updating the accounts: global mortality of the 1918-1920 ''Spanish'' influenza pandemic. Bull. Hist. Med. 76: 105-115.
68. Kaiser, L., R. S. Fritz, S. E. Straus, L. Gubareva, F.G. Hayden. 2001. Symptom pathogenesis during acute influenza: interleukin-6 other cytokine responses. J. Med. Virol. 64:262-268.
69. Kaiser, L., F.G. Hayden. 1999. Hospitalizing influenza in adults. Curr. Clin. Top. Infect. Dis. 19:112-134.
70. Keyser, L. A., M. Karl, A. N. Nafziger, J.S. Bertino. Jr. 2000. Comparison of central nervous system adverse effects of amantadine rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med. 160:1485-1488.
71. Kilbourne, E. D. 1987. Influenza. Plenum Medical Book Company, New York, NY.
72. Kobasa, D., S. M. Jones, K. Shinya, J. C. Kash, J. Copps, H. Ebihara, Y. Hatta, J. Hyun Kim, P. Halfmann, M. Hatta, F. Feldmann, J. B. Alimonti, L. Fernando, Y. Li, M. G. Katze, H. Feldmann, Y. Kawaoka. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-323.
73. Koelle, K., S. Cobey, B. Grenfell, M. Pascual. 2006. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 314:1898-1903.
74. Lamb, R. A. 1983. The influenza virus RNA segments their encoded proteins, p. 21. In P. Palese D.W. Kingsbury (ed.), Genetics of Influenza Viruses. SpringerVerlag, New York, NY.
75. Langmuir, A. D., T. D. Worthen, J. Solomon, C. G. Ray, E. Petersen. 1985. The Thucydides syndrome. A new hypothesis for the cause of the plague of Athens. N. Engl. J. Med. 313:1027-1030.
76. Lee, N., C. K. Wong, P. K. S. Chan, S. W. M. Lun, G. Lui, B. Wong, D. S. C. Hui, C. W. K. Lam, C. S. Cockram, K. W. Choi, A. C. M. Yeung, J. W. Tang, J.J. Y. Sung. 2007. Hypercytokinemia hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin. Infect. Dis. 45:723-731.
77. Leekha, S., N. Zitterkopf, M. J. Espy, T. F. Smith, R. L. Thompson, P. Sampathkumar. 2007. Duration of influenza a virus shedding in hospitalized patients implications for infection control. Infect. Control Hosp. Epidemiol. 28:1071-1076.
78. Leroux-Roels, I., A. Borkowski, T. Vanwolleghem, M. Drame, F. Clement, E. Hons, J. M. Devaster, G. Leroux-Roels. 2007. Antigen sparing cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589.
79. Lin, J. C., K.L. Nichol. 2001. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. 161:441-446.
80. Lin, Y. P., M. Shaw, V. Gregory, K. Cameron, W. Lim, A. Klimov, K. Subbarao, Y. Guan, S. Krauss, K. Shortridge, R. Webster, N. Cox, A. Hay. 2000. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 H5N1 human isolates. Proc. Natl. Acad. Sci. USA 97:9654-9658.
81. Lofgren, E., N. H. Fefferman, Y. N. Naumov, J. Gorski, E.N. Naumova. 2007. Influenza seasonality: underlying causes modeling theories. J. Virol. 81:54295436.
82. Lowen, A. C., S. Mubareka, J. Steel, P. Palese. 2007. Influenza virus transmission is dependent on relative humidity temperature. PloS Pathog. 3:14701476.
83. Lowen, A. C., S. Mubareka, T. M. Tumpey, A. Garcia-Sastre, P. Palese. 2006. The guinea pig as a transmission model for human influenza viruses. Proc. Natl. Acad. Sci. USA 103:9988-9992.
84. Luke, T. C., E. M. Kilbane, J. L. Jackson, S.L. Hoffman. 2006. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145:599-609.
85. Ma, W., A. L. Vincent, M. R. Gramer, C. B. Brockwell, K. M. Lager, B. H. Janke, P. C. Gauger, D. P. Patnayak, R. J. Webby, J.A. Richt. 2007. Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. USA 104:20949-20954.
86. Maines, T. R., L. M. Chen, Y. Matsuoka, H. Chen, T. Rowe, J. Ortin, A. Falcon, N. T. Hien, L. Q. Mai, E. R. Sedyaningsih, S. Harun, T. M. Tumpey, R. O. Donis, N. J. Cox, K. Subbarao, J.M. Katz. 2006. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc. Natl. Acad. Sci. USA 103: 12121-12126.
87. Markel, H., H. B. Lipman, J. A. Navarro, A. Sloan, J. R. Michalsen, A. M. Stern, M.S. Cetron. 2007. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 298:644-654.
88. Marsh, G. A., R. Hatami, P. Palese. 2007. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J. Virol. 81:9727-9736.
89. Martin, K., A. Helenius. 1991. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export inhibits import. Cell 67: 117-130.
90. Matsuzaki, Y., C. Abiko, K. Mizuta, K. Sugawara, E. Takashita, Y. Muraki, H. Suzuki, M. Mikawa, S. Shimada, K. Sato, M. Kuzuya, S. Takao, K. Wakatsuki, T. Itagaki, S. Hongo, H. Nishimura. 2007. A nationwide epidemic of influenza c virus infection in Japan in 2004. J. Clin. Microbiol. 45:783-788.
91. Matsuzaki, Y., N. Katsushima, Y. Nagai, M. Shoji, T. Itagaki, M. Sakamoto, S. Kitaoka, K. Mizuta, H. Nishimura. 2006. Clinical features of influenza C virus infection in children. J. Infect. Dis. 193:1229-1235.
92. McElhaney, J. E., J. W. Hooton, N. Hooton, R.C. Bleackley. 2005. Comparison of single versus booster dose of influenza vaccination on humoral cellular immune responses in older adults. Vaccine 23:3294-3300.
93. McElhaney, J. E., D. Xie, W. D. Hager, M. B. Barry, Y. Wang, A. Kleppinger, C. Ewen, K. P. Kane, R.C. Bleackley. 2006. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176:63336339.
94. McGeer, A., K. Green, A. Plevneshi, A. Shigayeva, N. Siddiqi, J. Raboud, D. Low. 2007. Antiviral therapy outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45:1568-1575.
95. McMichael, A. 1994. Cytotoxic T lymphocytes specific for influenza virus. Curr. Top. Microbiol. Immunol. 189: 75-91.
96. McMinn, P., A. Carrello, C. Cole, D. Baker, A. Hampson. 1999. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community. Clin. Infect. Dis. 29:456-458.
97. Monto, A. S., S. Gravenstein, M. Elliott, M. Colopy, J. Schweinle. 2000. Clinical signs symptoms predicting influenza infection. Arch. Intern. Med. 160:32433247.
98. Mulder, J., J.E. Hers. 1972. Influenza. Wolters-Noordhoof, Groningen, The Netherlands.
99. Munster, V. J., E. de Witt, D. van Riel, W. E. Beyer, G. F. Rimmelzwaan, A. D. Osterhaus, T. Kuiken, R.A. Fouchier. 2007. The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. J. Infect. Dis. 196:258-265.
100. Muraki, Y., T. Murata, E. Takashita, Y. Matsuzaki, K. Sugawara, S. Hongo. 2007. A mutation on influenza C virus Ml protein affects virion morphology by altering the membrane affinity of the protein. J. Virol. 81:8766-8773.
101. Murphy, B. R., M.L. Clements. 1989. The systemic mucosal immune response of humans to influenza A virus. Curr. Top. Microbiol. Immunol. 146: 107-116.
102. Murray, C. J., A. D. Lopez, B. Chin, D. Feehan, K.H. Hill. 2006. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 368:2211-2218.
103. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896903.
104. Myers, K. P., C. W. Olsen, G.C. Gray. 2007. Cases of swine influenza in humans: a review of the literature. Clin. Infect. Dis. 44:1084-1088.
105. Neirynck, S., T. Deroo, X. Saelens, P. Vanlandschoot, W. M. Jou, W. Fiers. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163.
106. Neumann, G., Y. Kawaoka. 2006. Host range restriction pathogenicity in the context of influenza pandemic. Emerg. Infect. Dis. 12:881-886.
107. Neumann, G., K. Shinya, Y. Kawaoka. 2007. Molecular pathogenesis of H5N1 influenza virus infections. Antivir. Ther. 12(4 Pt. B):617-626.
108. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96:9345-9350.
109. Neuraminidase Inhibitor Susceptibility Network. 2007. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly. Epidemiol. Rec. 82:149-150.
110. Neuzil, K. M., B. G. Mellen, P. F. Wright, E. F. Mitchel, Jr., M.R. Griffin. 2000. The effect of influenza on hospitalizations, outpatient visits, courses of antibiotics in children. N. Engl. J. Med. 342:225231.
111. Ng, W. F., K. F. To, W. W. L. Lam, T. K. Ng, K.C. Lee. 2006. The comparative pathology of severe acute respiratory syndrome avian influenza A subtype H5N1-a review. Hum. Pathol. 37:381-390.
112. Nichol, K. L., J. D. Nordin, D. B. Nelson, J. P. Mullooly, E. Hak. 2007. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357:1373-1381.
113. Nicholson, K. G. 1998. Human influenza, p. 219-264. In K.G. Nicholson, R. G. Webster, A.J. Hay (ed.), Textbook of Influenza. Blackwell Science Ltd., Oxford, United Kingdom.
114. Noyola, D. E., B. Clark, F. T. O'Donnell, R. L. Atmar, J. Greer, G.J. Demmler. 2000. Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, culture for rapid detection of influenza A B viruses in nasal wash specimens. J. Clin. Microbiol. 38:1161-1165.
115. Ohmit, S. E., J. C. Victor, J. R. Rotthoff, E. R. Teich, R. K. Truscon, L. L. Baum, B. Rangarajan, D. W. Newton, M. L. Boulton, A.S. Monto. 2006. Prevention of antigenically drifted influenza by inactivated live attenuated vaccines. N. Engl. J. Med. 355: 2513-2522.
116. Olsen, B., V. J. Munster, A. Wallensten, J. Waldenstrom, A. D. M. E. Osterhaus, R.A. M. Fouchier. 2006. Global patterns of influenza A virus in wild birds. Science 312:384-388.
117. O'Neill, R. E., R. Jaskunas, G. Blobel, P. Palese, J. Moroianu. 1995. Nuclear import of influenza virus RNA can be mediated by viral nucleoprotein transport factors required for protein import. J. Biol. Chem. 270:22701-22704.
118. O'Neill, R. E., J. Talon, P. Palese. 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J. 17:288296.
119. Ong, A. K., F.G. Hayden. 2007. John F. Enders Lecture 2006: antivirals for influenza. J. Infect. Dis. 196: 181-190.
120. Ozawa, M., H. Goto, T. Horimoto, Y. Kawaoka. 2007. An adenovirus vector-mediated reverse genetics system for influenza A virus generation. J. Virol. 81: 9556-9559.
121. Palese, P. 2004. Influenza: old new threats. Nat. Med. 10(12 Suppl.):S82-S87.
122. Palese, P., M. Shaw. 2007. Orthomyxoviridae: the viruses their replication, p. 1647-1689. In D.M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, S.E. Straus (ed.), Fields Virology, 5th ed. Lippencott Williams & Wilkins, Philadelphia, PA.
123. Pasick, J., K. Handel, J. Robinson, J. Copps, D. Ridd, K. Hills, H. Kehler, C. Cottam-Birt, J. Neufeld, Y. Berhane, S. Czub. 2005. Intersegmental recombination between the haemagglutinin matrix genes was responsible for the emergence of a highly pathogenic H7N3 avian influenza virus in British Columbia. J. Gen. Virol. 86:727-731.
124. Peiris, J. S. M., M. D. de Jong, Y. Guan. 2007. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20:243-267.
125. Peltola, V. T., K. G. Murti, J.A. McCullers. 2005. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J. Infect. Dis. 192:249-257.
126. Perez-Ruiz, M., R. Yeste, M. J. Ruiz-Perez, A. Ruiz-Bravo, M. de la Rosa-Fraile, J.M. Navarro-Mari. 2007. Testing of diagnostic methods for detection of influenza virus for optimal performance in the context of an influenza surveillance network. J. Clin. Microbiol. 45: 3109-3110.
127. Petric, M., L. Comanor, C.A. Petti. 2006. Role of the laboratory in diagnosis of influenza during seasonal epidemics potential pandemics. J. Infect. Dis. 194(Suppl. 2):S98-S110.
128. Poehling, K. A., K. M. Edwards, G. A. Weinberg, P. Szilagyi, M. A. Staat, M. K. Iwane, C. B. Bridges, C. G. Grijalva, Y. Zhu, D. I. Bernstein, G. Herrera, D. Erdman, C. B. Hall, R. Seither, M.R. Griffin for the New Vaccine Surveillance Network. 2006. The underrecognized burden of influenza in young children. N. Engl. J. Med. 355:31-40.
129. Potter, C. W. 1998. Chronicle of influenza pandemics, p. 3-18. In K.G. Nicholson, R. G. Webster, A.J. Hay (ed.), Textbook of Influenza. Blackwell Science Ltd., Oxford, United Kingdom.
130. 128a.Rasmussen, S. A., D. J. Jamieson, J.S. Bresee. 2008. Pandemic influenza pregnant women. Emerg. Infect. Dis. 14:95-100.
131. Reichert, T. A., N. Sugaya, D. S. Fedson, W. P. Glezen, L. Simonsen, M. Tashiro. 2001. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344:889-896.
132. Rimmelzwaan, G. F., A. C. Boon, J. T. Voeten, E. G. Berkhoff, R. A. Fouchier, A.D. Osterhaus. 2004. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res. 103(1-2):97-100.
133. Rodriguez, W. J., C. B. Hall, R. Welliver, E. A. Simoes, M. E. Ryan, H. Stutman, G. Johnson, R. Van Dyke, J. R. Groothuis, J. Arrobio, K. Schabel, H. W. Kim, R. H. Parrott, P. Pincus. 1994. Efficacy safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J. Pediatr. 125:129-135.
134. Rothbarth, P. H., J. Groen, A. M. Bohnen, R. de Groot, A.D. Osterhaus. 1999. Influenza virus serology-a comparative study. J. Virol. Methods 78(1-2): 163-169.
135. Roti, M., J. Yang, D. Berger, L. Huston, E. A. James, W.W. Kwok. 2008. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J. Immunol. 180:1758-1768.
136. Russell, C. A., T. C. Jones, I. G. Barr, N. J. Cox, R. J. Garten, V. Gregory, I. D. Gust, A. W. Hampson, A. J. Hay, A. C. Hurt, J. C. de Jong, A. Kelso, A. I. Klimov, T. Kageyama, N. Komadina, A. S. Lapedes, Y. P. Lin, A. Mosterin, M. Obuchi, T. Odagiri, A. D. M. E. Osterhaus, G. F. Rimmelzwaan, M. W. Shaw, E. Skepner, K. Stohr, M. Tashiro, R. A. M. Fouchier, D.J. Smith. 2008. The global circulation of seasonal influenza A (H3N2) viruses. Science 320:340-346.
137. Salgado, C. D., B. M. Farr, K. K. Hall, F.G. Hayden. 2002. Influenza in the acute hospital setting. Lancet Infect. Dis. 2:145-155.
138. Salomon, R., E. Hoffmann, R.G. Webster. 2007. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl. Acad. Sci. USA 104:12479-12481.
139. Salvatore, M., A. Garcia-Sastre, P. Ruchala, R. I. Lehrer, T. Chang, M.E. Klotman. 2007. a-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J. Infect. Dis. 196:835-843.
140. Schaffer, F. L., M. E. Soergel, D.C. Straube. 1976. Survival of airborne influenza virus: effects of propagating host, relative humidity, composition of spray fluids. Arch. Virol. 51:263-273.
141. Schwarzmann, S. W., J. L. Adler, R. J. Sullivan, W.M. Marine. 1971. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch. Intern. Med. 127:1037-1041.
142. Sidwell, R. W., D. L. Barnard, C. W. Day, D. F. Smee, K. W. Bailey, M. H. Wong, J. D. Morrey, Y. Furuta. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-851.
143. Simonsen, L., M. J. Clarke, L. B. Schonberger, N. Arden, N. J. Cox, K. Fukuda. 1998. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178:53-60.
144. Simonsen, L., R. J. Taylor, C. Viboud, M. A. Miller, L.A. Jackson. 2007. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis. 7:658-666.
145. Skowronski, D., S. A. Tweed, G. De Serres. 2008. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J. Infect. Dis. 197: 490-502.
146. Smith, G. J. D., X. H. Fan, J. Wang, K. S. Li, K. Qin, J. X. Zhang, D. Vijaykrishna, C. L. Cheung, K. Huang, J. M. Rayner, J. S. M. Peiris, H. Chen, R. G. Webster, Y. Guan. 2006. Emergence predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. USA 103:16936-16941.
147. Stech, J., H. Garn, M. Wegmann, R. Wagner, H.D. Klenk. 2005. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat. Med. 11:683-689.
148. Subbarao, K., I. Klimov, J. Katz, H. Regnery, W. Lim, H. Hall, M. Perdue, D. Swayne, C. Bender, J. Huang, M. Hemphill, T. Rowe, M. Shaw, X. Xu, K. Fukuda, N. Cox. 1998. Characterization of an avian influenza A(H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396.
149. Subbarao, K., T. Joseph. 2007. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 7:267-278.
150. Sugaya, N., K. Mitamura, M. Yamazaki, D. Tamura, M. Ichikawa, K. Kimura, C. Kawakami, M. Kiso, M. Ito, S. Hatakeyama, Y. Kawaoka. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202.
151. Sullivan, P. S., D. L. Hanson, M. S. Dworkin, J. L. Jones, J. W. Ward, the Adult Adolescent Spectrum of HIV Disease Investigators. 2000. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 14:2781-2785.
152. Taubenberger, J. K., A. H. Reid, R. M. Lourens, R. Wang, G. Jin, T.G. Fanning. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature 437:889-893.
153. Tecle, T., M. R. White, E. C. Crouch, K.L. Hartshorn. 2007. Inhibition of influenza viral neuraminidase activity by collectins. Arch. Virol. 152:1731-1742.
154. Temperton, N. J., K. Hoschler, D. Major, C. Nicolson, R. Manvell, V. M. Hien, D. Q. Ha, M. de Jong, M. Zambon, Y. Takeuchi, R.A. Weiss. 2007. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 1: 105-112.
155. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, C. B. Bridges, N. J. Cox, K. Fukuda. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
156. Thompson, W. W., L. Comanor, D.K. Shay. 2006. Epidemiology of seasonal influenza: use of surveillance data statistical models to estimate the burden of disease. J. Infect. Dis. 194(Suppl. 2):S82-S91.
157. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, M. Wolff. 2006. Safety immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
158. Treanor, J. J., F.G. Hayden. 2005. Viral infections, p. 867-919. In J.F. Murray J.A. Nadel (ed.), Textbook of Respiratory Medicine. W. B. Saunders Company, Philadelphia, PA.
159. Treanor, J. J., G. M. Schiff, F. G. Hayden, R. C. Brady, C. M. Hay, A. L. Meyer, J. Holden-Wiltse, H. Liang, A. Gilbert, M. Cox. 2007. Safety immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297: 1577-1582.
160. Tumpey, T. M., C. F. Basler, P. V. Aguilar, H. Zeng, A. Solorzano, D. E. Swayne, N. J. Cox, J. M. Katz, J. K. Taubenberger, P. Palese, A. Garcia-Sastre. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77-80.
161. Tumpey, T. M., T. R. Maines, N. Van Hoeven, L. Glaser, A. Solorzano, C. Pappas, N. J. Cox, D. E. Swayne, P. Palese, J. M. Katz, A. Garcia-Sastre. 2007. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 315: 655-659.
162. van Riel, D., V. J. Munster, E. de Wit, G. F. Rimmelzwaan, R. A. M. Fouchier, A. D. M. E. Osterhaus, T. Kuiken. 2007. Human avian influenza viruses target different cells in the lower respiratory tract of humans other mammals. Am. J. Pathol. 171: 1215-1223.
163. Wang, J. P., E. A. Kurt-Jones, R.W. Finberg. 2007. Innate immunity to respiratory viruses. Cell. Microbiol. 9:1641-1646.
164. Webster, R. G., E.A. Govorkova. 2006. H5N1 influenza-continuing evolution spread. N. Engl. J. Med. 355:2174-2177.
165. Wiley, D. C., J.J. Skehel. 1987. The structure function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56:365-394.
166. World Health Organization. 2007. Clinical management of human infection with avian influenza A (H5N1) virus. http://www.who.int/csr/disease/avian_ influenza/ guidelines / ClinicalManagement07.pdf.
167. World Health Organization. 2008. WHO/ECDC frequently asked questions for oseltamivir resistance. http://www.who.int/csr/disease/influenza/oseltamivir_ faqs /en/ print.html.
168. Wright, P., G. Neumann, Y. Kawaoka. 2007. Orthomyxoviruses, p. 1691-1740. In D.M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, S.E. Straus (ed.), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
169. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
170. Yamada, S., Y. Suzuki, T. Suzuki, M. Q. Le, C. A. Nidom, Y. Sakai-Tagawa, Y. Muramoto, M. Ito, M. Kiso, T. Horimoto, K. Shinya, T. Sawada, M. Kiso, T. Usui, T. Murata, Y. Lin, A. Hay, L. F. Haire, D. J. Stevens, R. J. Russell, S. J. Gamblin, J. J. Skehel, Y. Kawaoka. 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382.
171. Yamashita, M., M. Krystal, P. Palese. 1989. Comparison of the three large polymerase proteins of influenza A, B, C viruses. Virology 171:458-466.
172. Yun, N. E., N. S. Linde, M. A. Zacks, I. G. Barr, A. C. Hurt, J. N. Smith, N. Dziuba, M. R. Holbrook, L. Zhang, J. M. Kilpatrick, C. S. Arnold, S. Paessler. 2008. Injectable peramivir mitigates disease promotes survival in ferrets mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374:198-209.